Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Reinnervate Completes Expansion into New Purpose-Built Facility at Netpark

Published: Tuesday, November 16, 2010
Last Updated: Tuesday, November 16, 2010
Bookmark and Share
Reinnervate, a life sciences company driving the adoption of routine 3D cell culture, has announced its expansion into a new purpose-built research and production facility at NETPark near Sedgefield, UK.

The move to the circa 10,000 square foot facility has enabled reinnervate to begin commercial production of its alvetex® 3D cell culture technology in readiness for its planned 4Q 2010 launch. Pictures of the new facility are available upon request.

The Company is also looking to recruit up to 30 new employees over the next 12 months in research, development production, sales and marketing in order to establish the use of alvetex® for routine 3D cell culture in academic and industry laboratories around the world.

Reinnervate, a Durham University spin-out, has spent nearly eight years developing its alvetex® technology based on pioneering research carried out by its founding scientist, Professor Stefan Przyborski. alvetex® is a unique and proprietary scaffold that enables routine 3D cell culture in the lab, i.e. more akin to the way cells grow in tissues in the human body than conventional 2D cell culture technologies, where cells grow in flat sheets.

The use of alvetex-derived 3D cell cultures is therefore expected to provide greater insight into how cells behave in the body in response to external factors (such as drug candidates) than is currently possible with existing 2D technologies.

In July 2010, reinnervate announced a further £1.8 million of equity investment from Newcastle-based NorthStar Equity Investment Limited and private investors to support the ongoing development and commercialisation of its alvetex® platform. Commercialisation is now at an advanced stage and reinnervate has begun discussions with major distributors of cell culture products in the UK and overseas to sell alvetex® in a range of formats for multiple, potential applications in academia and in the pharmaceutical and related sectors.
The Company’s move into NETPark has been made possible by County Durham Development Company (CDDC), which develops, manages and promotes the North East Technology Park near Sedgefield on behalf of Durham County Council.  CDDC project managed the development of reinnervate’s specialist production facility and associated laboratories.

Ashley Cooper, CEO of reinnervate, commented: “We are delighted and proud to be moving to this larger, purpose-built facility at NETPark and we are hugely grateful to CDDC and its staff for their support and assistance in this programme. The capabilities we can now access will allow the Company to advance to the next stage in its development as we prepare for the official commercial launch of alvetex® later this year. Over the next 12 months, we will be looking to recruit up to 30 new employees to rapidly expand our production and sales operations and our new facility gives us the necessary space to meet our ambitious growth targets.”

Stewart Watkins, Managing Director of CDDC added: “This is a really good example of how the public and private sectors can collaborate to exploit new business opportunities and create much needed employment in the area. Reinnervate is a hugely important company to NETPark and County Durham – it has fantastic technology, a highly experienced management team and a great market proposition. It exemplifies the kind of company we want to attract and support, and is a very welcome addition to the NETPark community.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reinnervate Partners with Oncotest and SBH Sciences
Companies to partner on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture.
Thursday, October 31, 2013
Reinnervate Ltd and Roslin Cellab Partner
Reinnervate Ltd announced that it is entering into a collaboration with Roslin Cellab to develop 3D stem cell printing products and services using Alvetex® technology.
Friday, September 20, 2013
3D cell Culture Firm Reinnervate and Specialist Oncology CRO Oncotest GmbH Enter Collaboration Agreement
Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating Alvetex®Scaffold 3D cell culture technology.
Monday, January 07, 2013
Reinnervate and Tecan Sign Co-marketing Agreement
Both Companies to develop automated 3D cell culture solutions for improved cellular assays.
Tuesday, November 27, 2012
Reinnervate and Roslin Cellab Announce Plans to Collaborate
Collaboration on the development of protocols for three dimensional growth of hESC’s using Alvetex®Scaffold.
Friday, April 27, 2012
Reinnervate and Kirkstall to Collaborate on New 3D Cell Culture Products
Companies will collaborate to bring next generation three dimensional (3D) cell culture products to market in 2012. The two UK companies develop cell culture systems that bridge the current gap between 2D in-vitro cell culture and animal models.
Monday, March 19, 2012
New Reinnervate Whitepaper Includes Details on Live 3D Cell Imaging in 3D Cell Culture Using Alvetex®
The release is set to help scientists make the switch from traditional 2D cell culture to 3D cell growth.
Monday, January 30, 2012
Reinnervate and Mirus Bio announce collaboration
Reinnervate and Mirus Bio announce commercial agreement to launch new range of products for the transfection of cells cultured in 3D.
Friday, November 18, 2011
Alvetex® Voted One of Most Technologically Significant New Research Products By R&D Magazine
Alvetex® enables genuine 3D cell growth to be performed routinely and cost effectively in cell biology laboratories.
Monday, June 27, 2011
Reinnervate Partners with AMS Biotechnology (Europe) Limited for Distribution of Alvetex®
Alvetex® is a unique and proprietary cell culture scaffold that enables genuine 3D cell growth to be performed routinely and cost-effectively in cell biology laboratories.
Wednesday, June 01, 2011
Reinnervate Enhances Commercial and Product Development Teams with Key Senior Appointments
Appointments of Richard Rowling as commercial director and Barry Lynch as marketing manager to lead the sales and marketing operations supporting alvetex®.
Wednesday, April 06, 2011
Alvetex® Named in the “Top Ten Life Science Innovations of 2010” by The Scientist Magazine
Reinnervate’s 3D cell culture technology selected as one the ten most exciting new tools to hit the life sciences market this year.
Monday, December 06, 2010
Reinnervate Partners with LGC for Global Distribution of Alvetex®
Additional collaboration to develop 3d cell cultures for applications in drug discovery and development.
Tuesday, November 30, 2010
Reinnervate Partners with LGC for Global Distribution of ALVETEX®
Additional collaboration to develop 3D cell cultures for applications in drug discovery and development.
Monday, November 29, 2010
Reinnervate Launches new Website with Interactive Technical Resource for Routine 3D Cell Culture
New site provides scientific and technical information on 3D cell culture based on Reinnervate’s core Alvetex® technology.
Wednesday, October 13, 2010
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!